Maze Therapeutics is a clinical-stage biopharmaceutical company developing small molecule precision medicines for kidney and metabolic diseases. The company utilizes its proprietary Compass platform to identify and characterize genetic variants associated with health and disease, applying this data to drug discovery and clinical trial design. Its pipeline includes MZE829, an oral APOL1 inhibitor in Phase 2 for APOL1-mediated kidney disease, and MZE782, an oral inhibitor in Phase 1 for phenylketonuria and chronic kidney disease. Maze also has a partnered program, MZE001, for Pompe disease licensed to Shionogi & Co., Ltd. The company targets patient populations with genetically defined conditions, including those of West African ancestry affected by APOL1 variants, and plans to commercialize its lead candidates in geographies where it can independently support adoption.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage mazetx.com
Sector Healthcare IR page ir.mazetx.com
Tags
precision medicine, kidney disease, metabolic disorders, small molecule drugs, genetics, chronic kidney disease, phenylketonuria, pompe disease, drug discovery, Compass platform, MZE829, MZE782, MZE001, S606001, Shionogi & Co. Ltd
Press page —

Metrics

Valuation  
Market cap $ 1.724B
Market cap (USD) $ 1.724B
P/E -12.37
PEG —
P/BV 4.02
P/S 10.29
P/OCF -15.03
P/FCF -14.96
Dividend yield —
Turnover / mcap —
Returns  
ROE -36.9%
ROI -71.2%
ROIC -58.2%
Profit margin —
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 9.1%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 16
Quality score -83.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022
Revenue — 167.5M 0 0
Net profit -131.12M 52.231M -100.415M -114.94M
Free cash flow -112.734M 74.807M -87.268M -101.169M

Figure FY 2025 FY 2024 FY 2023 FY 2022
Share price 41.43 — — —
P/FCF -18.13 — — —

Filed figures

Figure Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — 26.6M 23.3M
Cash and deposits (USD) 30.2M 197M 189M
Right-of-use assets (USD) — 23.3M 20.1M
Cash flow detail
Operating cash flow (USD) — 76M -112M
Purchases of property, plant and equipment (USD) — -1.15M -794,000
Change in payables (cash effect) (USD) — -204,000 -27,000
Income taxes paid (cash effect) (USD) — -1.23M —
Share-based compensation (USD) — 9.65M 16.4M
Free cash flow (OCF - PPE - intangibles) (USD) — 74.8M -113M
Income detail
Research and development expense (USD) — 83.5M 108M
Total comprehensive income (USD) — 52.2M -131M
Comprehensive income to owners (USD) — 52.2M -131M
Reported May 14, 2025 Mar 25, 2026 Mar 25, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Enrollment completed in Phase 2 HORIZON trial of MZE829; data from all three cohorts expected in early 2027

Enrollment ongoing in Phase 2 CIPheR trial of MZE782 in PKU; topline data expected in 2027

Phase 2 trial of MZE782 in CKD on track for H1 2027 initiation

Strong balance sheet with $477 million in cash, cash equivalents and marketable securities as of September 30, 2026 supports expected runway into 2029

SOUTH SAN FRANCISCO, Calif., November 9, 2026 (GLOBE NEWSWIRE) – Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today reported financial results for the third quarter ended September 30, 2026, highlighting recent progress and business updates.

“Completing enrollment in HORIZON with more than 50 patients across three cohorts marks an important milestone for MZE829 and exceeded our target enrollment of 10-15 patients per cohort,” said Jason Coloma, Ph.D., chief executive officer of Maze.

November 3, 2026

PDF Version

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that Jason Coloma, Ph.D., chief executive officer of Maze Therapeutics, will participate in three upcoming investor conferences:

  • 3rd Annual Guggenheim Healthcare Innovation Conference; fireside chat on Tuesday, November 10, 2026, at 2:00 p.m. ET

  • 2026 Jefferies Global Healthcare Conference in London; presentation on Tuesday, November 17, 2026, at 10:30 a.m. ET / 3:30 p.m. GMT

  • 9th Annual Evercore Healthcare Conference; fireside chat on Tuesday, December 1, 2026, at 9:35 a.m. ET

Live webcasts of the events will be available in the Investors section of the Maze Therapeutics website at www.mazetx.com and archived for 60 days following the presentations.

About Maze Therapeutics

Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel small molecule precision medicines for patients with kidney and metabolic diseases. Guided by its Compass™ platform, Maze pursues genetically validated targets by integrating variant discovery and functionalization to discover and advance small molecule programs with first- or best-in-class potential. Maze’s pipeline is led by MZE829, a dual-mechanism APOL1 inhibitor in Phase 2 development for APOL1-mediated kidney disease (AMKD), and MZE782, a SLC6A19 inhibitor in Phase 2 development with the potential to treat both phenylketonuria (PKU) and chronic kidney disease (CKD). Maze is headquartered in South San Francisco. For more information, please visit mazetx.com, or follow Maze on LinkedIn and X.

IR/Corporate Contact: Argot Partners [email protected]

Media Contact: Amanda Lazaro, 1AB Media [email protected]

The information contained below under Item 3.02 is hereby incorporated by reference in response to this Item 1.01 of Form 8-K.

Unregistered Sales of Equity Securities

On October 15, 2026, Maze Therapeutics, Inc. (“Maze”) entered into an exchange agreement (the “Exchange Agreement”) with Frazier Life Sciences Public Fund, L.P., Frazier Life Sciences X, L.P., Frazier Life Sciences XI, L.P. and Frazier Life Sciences XII, L.P. (collectively, the “Exchanging Stockholder”), pursuant to which Maze exchanged an aggregate of 2,776,007 shares of Maze’s common stock, par value $0.001 per share (the “Common Stock”), held by the Exchanging Stockholder for pre-funded warrants (the “Exchange Warrants”) to purchase an aggregate of 2,776,007 shares of Common Stock (subject to adjustment in the event of stock splits, recapitalizations and other similar events affecting Common Stock), with an exercise price of $0.001 per share. After giving effect to the exchange of 2,776,007 shares of Common Stock for the Exchange Warrants, the number of shares of Maze’s outstanding Common Stock as of October 16, 2026 is 53,931,889.

Prompts

Maze Therapeutics, Inc. (ticker MAZE), listed in United States.

ETFs Holding Maze Therapeutics, Inc.

ETF Weight in ETF Shares Market value As of
SCDS 0.24% 655 $ 21.53K Nov 17, 2026
TMED 0.21% 1,656 $ 49.415K Jun 30, 2026
FSML 0.06% 2,433 $ 72.601K Jun 30, 2026
TCAF 0.05% 169,417 $ 5.743M Nov 17, 2026
FESM 0.02% 30,178 $ 900.512K Jun 30, 2026
DCOR 0.00% 33,496 $ 1.209M Nov 12, 2026
DFAS 0.00% 23,101 $ 833.715K Nov 12, 2026
DFAC 0.00% 32,019 $ 1.156M Nov 12, 2026
DFUS 0.00% 4,508 $ 162.694K Nov 12, 2026
ESSC 0.00% 10 $ 269.20 Jul 31, 2026
DFAU 0.00% 1,858 $ 67.055K Nov 12, 2026